SCHEMBL847737

SCHEMBL847737

Cc1ccc(C(=O)CCc2ccc(S(C)(=O)=O)nc2)c(Nc2ccccc2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 6/20 0.38
▸ STAT6 P42226 1/20 0.37
▸ MAPK8 P45983 1/20 0.35
▸ NAMPT P43490 1/20 0.35
▸ IGF1R P08069 1/20 0.35
▸ ZAP70 P43403 1/20 0.34
▸ SYK P43405 1/20 0.34
▸ EGFR P00533 2/20 0.34
▸ ITK Q08881 1/20 0.34
▸ DAGLA Q9Y4D2 1/20 0.34
▸ AXL P30530 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ MERTK Q12866 1/20 0.34
▸ BTK Q06187 1/20 0.34
▸ ACLY P53396 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC7 Q8WUI4 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL846959 0.85 FFAR1 (0.40) PDE4BSTAT6MAPK8NAMPTIGF1R
SCHEMBL847744 0.85 STAT6 (0.39) PDE4BSTAT6MAPK8IGF1RZAP70
SCHEMBL846971 0.84 STAT6 (0.38) PDE4BSTAT6MAPK8IGF1RZAP70
SCHEMBL847717 0.83 KMT2A (0.42) PDE4BSTAT6MAPK8NAMPTEGFR
SCHEMBL848421 0.82 FAAH (0.41) STAT6HDAC3HDAC1HDAC2
SCHEMBL849127 0.81 STAT6 (0.37) PDE4BSTAT6MAPK8IGF1RZAP70
SCHEMBL848924 0.80 CYP1A2 (0.44) NAMPT
SCHEMBL846972 0.73 MAPT (0.36) PDE4BSTAT6MAPK8ZAP70SYK
SCHEMBL14617173 0.73 GAA (0.46) PDE4BMAPK8ZAP70SYKEGFR
SCHEMBL847983 0.72 ALDH1A1 (0.44) EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163906-B2 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO, LLC (US) 2012-04-24 — — US disclosed
EP-2148862-B1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK HOFFMANN LA ROCHE (CH) 2012-03-28 — — EP disclosed
EP-2148862-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. Hoffmann-Roche AG (CH) 2010-02-03 — — EP disclosed
WO-2009015917-A2 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 — — WO disclosed
WO-2008138920-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 — — WO disclosed
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO LLC 2008-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK MAPK9, MAPK10, MAPK1 PDE4B 4145/4885STAT6 611/4885MAPK8 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback